Skip to main content

entrectinib

Generic: ENTRECTINIB·Brand: ROZLYTREK, Rozlytrek

entrectinib: 7 clinical trials tracked.

entrectinib evidence translation

What we can confirm

7 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about entrectinib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (7)

PHASE 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (GLOBOTRK)

NCT06528691Registry updated 2026-02-17·Phase 2
Recruiting

Primary endpoint: Overall response rate (ORR) (Cohort 1)

Interventionalopen52 targetStarted 2026-03Completion 2032-112 sites · Jordan, United StatesSt. Jude Children's Research Hospital

An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study

NCT05862285Registry updated 2026-02-13·Phase 3
Recruiting

Primary endpoint: Number of Participants With Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s)

Interventionalopen100 targetStarted 2023-06Completion 2033-0350 sites · Belgium, Canada, China, Costa Rica…Hoffmann-La Roche

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations

NCT05722886Registry updated 2026-07-01·Phase 2/Phase 3
Recruiting

Primary endpoint: Number of patients who consent to each arm.

Interventionalopen825 targetStarted 2023-03Completion 2029-1027 sites · United KingdomCancer Research UK

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

NCT04589845Registry updated 2026-02-09·Phase 2
Recruiting

Primary endpoint: All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Interventionalopen920 targetStarted 2021-01Completion 2032-0950 sites · United StatesHoffmann-La Roche

NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer

NCT04302025Registry updated 2026-02-09·Phase 2
Recruiting

Primary endpoint: Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)

Interventionalopen99 targetStarted 2020-11Completion 2030-0538 sites · United StatesGenentech, Inc.

Genomically-Guided Treatment Trial in Brain Metastases

NCT03994796Registry updated 2026-09-28·Phase 2
Active, not recruiting

Primary endpoint: Objective response rate in the brain

Interventionalopen50 enrolledStarted 2019-10Completion 2028-06435 sites · United StatesAlliance for Clinical Trials in Oncology

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

NCT02925234Registry updated 2024-01-24·Phase 2
Recruiting

Primary endpoint: Percentage of patients that are treated based on their molecular tumor profile

Interventionalopen1,550 targetStarted 2016-08Completion 2027-1236 sites · NetherlandsThe Netherlands Cancer Institute